Filing summary
Entity discrepancy: The supplied filing is BioDrain Medical, Inc.’s Form 10-Q for the quarter ended March 31, 2012, not a filing identified as Axe Compute Inc. The summary below reflects the filing text.
Business context and reporting period
BioDrain Medical is a development-stage medical-device company developing the STREAMWAY fluid management system and related cleaning supplies for surgical and post-operative care. The company received FDA clearance in 2009, but sales remained limited. This unaudited filing covers the three months ended March 31, 2012, compared with the same 2011 quarter.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Revenue | $22,635 | $0 |
| Cost of goods sold | $13,806 | $0 |
| Gross profit / margin | $8,829 / approximately 39% | No revenue |
| Net loss | $713,367 | $477,433 |
| Loss per share, basic and diluted | $0.02 | $0.03 |
| Operating cash used | $250,249 | $367,405 |
| Cash from financing | $149,657 | $689,291 |
| Cash at quarter-end | $22,393 | $331,269 at March 31, 2011 |
General and administrative expense rose to $565,721 from $312,954, including $300,000 of investor stock compensation. Operations expense fell to $69,737 from $91,591; sales and marketing expense increased to $31,900 from $19,724. Interest expense was $55,488 versus $57,892. The company reported a $650 gain from revaluation of equity-linked instruments, compared with a $4,728 gain.
At March 31, total assets were $340,721, current assets $195,680, current liabilities $2,581,877, long-term debt $546,600, and stockholders’ deficit $2,953,168. The balance sheet reports $1,227,042 of current convertible debt, net of discounts. The debt note lists total debt of $1,388,985, of which $842,385 was due within one year. Accounts payable were $728,291 and accrued expenses $626,544. These figures indicate severe liquidity pressure; cash declined by $100,592 during the quarter.
Material changes, outlook, and risks
- Quarterly revenue came from disposable supplies purchased by customers that acquired units in 2011; the filing reports no billable unit sales for the quarter. Management said hospital evaluations and approvals could lead to future unit orders, but timing and volume were uncertain.
- Management said 2012 revenue was not expected to fund operating needs and estimated at least $2 million of additional financing would be needed to fund the next 12 months. The company warned that financing might not be available and that losses would continue.
- As of May 7, 2012, $682,000 of principal and accrued interest was past due and in default. Holders of debt representing $382,000 had threatened legal action; the company warned of litigation costs, judgments, or possible involuntary bankruptcy.
- Related-party financing included 20% convertible notes secured by substantially all company assets: a SOK Partners facility of up to $600,000, due August 2012, and a $240,000 Herschkowitz note due June 2012. The filing says an event of default occurred under the Herschkowitz note; 7.5 million additional shares were transferred to the lender in April 2012, and negotiations continued. SOK financing terms also included equity bonuses and restrictions on other financing without consent.
- Management stated recurring losses and stockholders’ deficit raised substantial doubt about the company’s ability to continue as a going concern. The financial statements include no adjustments for that uncertainty.
- Disclosure controls were deemed ineffective as of March 31, 2012. Management identified a material weakness involving the recording and reconciliation of options and warrants and was implementing remediation. A former sales executive’s lawsuit alleging breach of contract and defamation was pending; the company said it intended to defend the action.
- Management cited risks including the ability to raise capital, generate sales, manage operating costs, adverse economic conditions, litigation, and retaining qualified management and sales personnel. It expected expenses to rise as it expanded sales and manufacturing capabilities.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing names BioDrain Medical, Inc., not Axe Compute Inc.
- Verify subsequent financing, the amount and status of overdue debt, defaults, creditor demands, and any restructuring or bankruptcy-related developments.
- Review the full terms and related-party implications of the SOK and Herschkowitz notes, including collateral, conversion, equity bonuses, default provisions, and share transfers.
- Check cash runway and whether the company obtained the stated additional financing needed for operations.
- Assess whether hospital evaluations converted into billable STREAMWAY orders and whether sales growth can support the company’s cost structure.
- Review dilution: common shares outstanding increased from 32,074,000 at year-end to 38,636,433 at March 31; the filing reports 46,686,911 shares outstanding as of May 10, 2012.
- Track remediation of the material weakness in financial reporting controls and the outcome of the former employee’s lawsuit.